News

ODU hires Associate VP for Innovation & Commercialization

Kevin Leslie will be Old Dominion University’s first associate vice president for innovation and commercialization, the Norfolk-based university announced Friday.

Leslie will improve ODU’s technology transfer operation to better identify, develop and market faculty, staff and student intellectual property and startups. He also will lead federal and other grant applications related to innovation and ecosystem building.

“Dr. Leslie will take ODU’s innovation and commercialization activities to the next level of success, as appropriate for an R1 institution,” Morris Foster, ODU vice president for research, said in a statement. “ODU will expand its role as Hampton Roads’ academic research and innovation leader.”

For the past two years, Leslie has served as the inaugural executive director of the Hampton Roads Biomedical Research Consortium, a state-sponsored partnership between ODU, Eastern Virginia Medical School, Norfolk State University and Sentara Healthcare to advance regional health equity and bio-health innovation. He worked with regional leadership to deploy $22 million in capital and operating funds, develop and implement strategic plans and build shared research infrastructure and resources.

“Building the Hampton Roads Biomedical Research Consortium helped me gain a deep understanding of the region and its institutions,” Leslie said in a statement. “As ODU’s role in Hampton Roads and the commonwealth continues to grow, I look forward to building on that knowledge to accelerate the translation of ideas from its labs and classrooms out into the world.”

Before leading the HRBRC, Leslie was associate director of Virginia Commonwealth University Ventures and helped lead Richmond’s Health Innovation Consortium, a public-private platform to support novel health care technologies.

Leslie holds bachelor’s and master’s degrees in biology from William & Mary. He has a doctorate in integrated life sciences from VCU.

He is a member of the Civic Leadership Institute’s 2023 Executive Program class and has served as adjunct faculty for the National Science Foundation Innovation Corps (I-Corps) program.

In his role, Leslie will work closely with Sarah Jane Kirkland, who ODU named associate vice president for corporate partnerships in December 2022.

 

Learn more here.

Recent News

09/03/2026

Seppic announces the appointment of Virginie Cavalli as Chief Executive Officer

A subsidiary of Air Liquide Healthcare, Seppic designs, manufactures, and distributes a wide range of specialty ingredients used in cosmetics, nutraceuticals, pharmaceuticals, veterinary products, and industrial applications. Nearly 900 employees support customers in 100 countries through the company’s subsidiaries and distributor network. With a degree from EMLyon school in business and financial strategy, Virginie Cavalli

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the